Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience-Reference-Cited by-同舟云学术

Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience

Published:2016-10 Issue: Volume:134 Page:58-62
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

El-Haddad Danielle^ORCID,El Chaer Firas,Vanichanan Jackapat^ORCID,Shah Dimpy P.,Ariza-Heredia Ella J.,Mulanovich Victor E.,Gulbis Alison M.,Shpall Elizabeth J.,Chemaly Roy F.

Funder

The University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference12 articles.

1. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro;Beadle;Antimicrob. Agents Chemother.,2002

2. How we treat cytomegalovirus in hematopoietic cell transplant recipients;Boeckh;Blood,2009

3. Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir;Chimerix Press Release,2015

4. Resistance of human cytomegalovirus to antiviral drugs;Erice;Clin. Microbiol. Rev.,1999

5. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses;Florescu;Expert Rev. Anti Infect. Ther.,2014

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Qualitative evaluation of connective tissue disease with cytomegalovirus infection: A meta-analysis of case reports;Seminars in Arthritis and Rheumatism;2024-04

2. Cytomegalovirus Infections in Hematopoietic Cell Transplant and Solid Organ Transplant Recipients;Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century;2024

3. Monkeypox Outbreak: an Overview of Potential Therapeutic Options;Current Treatment Options in Infectious Diseases;2023-09-07

4. A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV;Cureus;2023-03-09

5. Immunomodulatory nanosystems: An emerging strategy to combat viral infections;Biomaterials and Biosystems;2023-03